MIZOBUCHI MASAHIDE

Research theme for competitive and other funds (8)：

2023 - 2026 CKDのリン代謝異常による新規臓器毒性の探究
2020 - 2024 Elucidation of Regulatory Mechanism of Vitamin D- Vitamin D Receptor System in Cardiovascular Tissues in Uremic Milieu
2018 - 2021 Vascular health and vitamin D under uremic condition
2017 - 2020 Establishment of Pathological Model of Skeletal resistance to PTH in Uremia using iPS Cells
2013 - 2016 Ca Load Induces Vascular Smooth Muscle Cell Mineralization Partly Mediated by TRPV

Show all

Papers (52)：

Ken Iseri, Masahide Mizobuchi, Kanji Shishido, Noriko Hida. Association between CKD-MBD and hip-bone microstructures in dialysis patients. Clinical kidney journal. 2024. 17. 8. sfae240
Tomohiro Saito, Masahide Mizobuchi, Mariko Sakai, Takehisa Kawata, Tetsuya Kitayama, Tadashi Kato, Taihei Suzuki, Hiroaki Ogata, Fumihiko Koiwa, Hirokazu Honda. Effects of evocalcet on parathyroid calcium-sensing receptor and vitamin D receptor expression in uremic rats. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2023. 37. 8. e23094
Ken Iseri, Masahide Mizobuchi, Renaud Winzenrieth, Ludovic Humbert, Tomohiro Saitou, Tadashi Kato, Yutaka Nakajima, Mikio Wakasa, Kanji Shishido, Hirokazu Honda. Long-Term Impact of Denosumab on Bone Disease in Patients with CKD. Clinical journal of the American Society of Nephrology : CJASN. 2023
Tomohiro Saito, Masahide Mizobuchi, Tadashi Kato, Hiroaki Ogata, Fumihiko Koiwa, Hirokazu Honda. Fibroblast Growth Factor 23 Exacerbates Cardiac Fibrosis in Deoxycorticosterone Acetate-Salt Mice With Hypertension. Laboratory investigation; a journal of technical methods and pathology. 2023. 103. 1. 100003-100003
Tomohiro Saito, Masahide Mizobuchi, Tadashi Kato, Taihei Suzuki, Yasuro Fujiwara, Naoaki Kanamori, Mikio Makuuchi, Hirokazu Honda. One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study. Calcified tissue international. 2022. 112. 1. 34-44

ｍore...

MISC (233)：

溝渕正英. カルシミメティクス治療の現状と課題. 秋田腎不全研究会誌. 2023. 26. 15-18
溝渕正英. 【現場のもやもやをスッキリ除く透析患者のくすりの疑問】最新Topics リン吸収阻害薬新規経口NHE3阻害薬テナパノル塩酸塩への期待. 薬事. 2023. 65. 12. 2463-2464
齋藤友広, 溝渕正英. 【CKD-MBDの新しい潮流】CKD-MBD関連因子がもたらす臓器障害心筋線維化とFGF23,ビタミンD代謝. 腎と透析. 2023. 95. 3. 283-286
溝渕正英. カルシウム感知受容体作動薬(カルシミメティクス)の薬物動態特性. 腎と透析. 2022. 93. 5. 797-804
溝渕正英. 討論すべき問題点を整理する c.PTHのコントロール. 日本透析医学会雑誌. 2022. 55. Suppl.1. 386-386

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page